Conversion of Injectable Semaglutide into Oral Formulations: Comparative Evaluation of Tablet and Liquid Preparations for Pharmaceutical Feasibility and Biological Potential

Abstract

The change of injectable semaglutide into verbally administered portion of drug or other consumable forms shows a significant progress in peptide-located diabetes medicines. This study evaluates the feasibility, pharmacokinetics, and temporary balance of oral semaglutide brought through capsule and liquid formulations in Sprague–Dawley rats. Injectable semaglutide (1 mg/mL) was reformulated using SNAC-located next-release sciences. Both oral formulations illustrated agreeable bioavailability (0.8–0.9%) relative to the injectable form. Pharmacokinetic reasoning told deferred T_max for the tablet distinguished to the liquid, unpaid to formulation excipients. Stability experiment over 30 days designated maintained potency (95–97%) accompanying gentle opalescence in the liquid expression, inciting plans for enhanced expression plannings. These judgments provide basic evidence advocating future long-term ICH-obedient support studies and expression refinement for numbering spoken GLP-1 agonist development.

References

1. Aroda, V.R.; et al. Efficacy and safety of oral semaglutide. Diabetes Care 2021, 44, 254–263.
2. Zinman, B.; et al. PIONEER 1 trial of oral semaglutide monotherapy. Diabetes Care 2019, 42, 1724–1733.
3. Husain, M.; et al. Oral semaglutide and cardiovascular outcomes. N. Engl. J. Med. 2019, 381, 841–851.
4. Htike, Z.Z.; et al. Efficacy and safety of oral GLP-1 agonists. Diabetes Ther. 2020, 11, 2791–2806.
5. Auck, M.A. Update on GLP-1 receptor agonists. Lancet Diabetes Endocrinol. 2021, 9, 653–664.
6. Granhall, C.; et al. Pharmacokinetics of oral semaglutide. Clin. Pharmacokinet. 2019, 58, 1415–1428.
7. Overgaard, R.V.; et al. Modeling the pharmacokinetics of semaglutide. CPT Pharmacometrics Syst. Pharmacol. 2020, 9, 195–205.
8. Baekdal, T.A.; et al. Gastric absorption mechanism of oral semaglutide. J. Control. Release 2021, 337, 221–230.
9. Marso, S.P.; et al. Semaglutide and cardiovascular outcomes in diabetes. N. Engl. J. Med. 2016, 375, 1834–1844.
10. Drucker, D.J. Mechanisms of GLP-1 receptor agonists. Cell Metab. 2020, 32, 188–202.
11. Knudsen, L.B.; et al. GLP-1 receptor agonists in obesity management. Int. J. Obes. 2023, 47, 117–125.US FDA. Rybelsus® approval summary. FDA.gov. 2019.
12. Novo Nordisk (Novo Nordisk A/S, Bagsværd, Denmark). Oral semaglutide stability data. Technical report, 2022. Unpublished work.
13. U.S. Food and Drug Administration (FDA). Rybelsus® approval summary. Available online: FDA.gov (accessed on 15 December 2019).